US Patent 8841249 Growth hormones with prolonged in-vivo efficacy

Patent 8841249 was granted and assigned to Novo Nordisk on September, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

88412490

Patent Inventor Names

Jens Buchardt0

Henrik Sune Andersen0

Leif Norskov-Lauritsen0

Nils Langeland Johansen0

Date of Patent

September 23, 2014

Patent Application Number

133891800

Date Filed

August 6, 2010

Patent Citations Received

‌

US Patent 12077795 Method for biocatalytic protein-oligonucleotide conjugation

Patent Primary Examiner

‌

Jeffrey E. Russel

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8841249 Growth hormones with prolonged in-vivo efficacy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API